Show results for
Refine by
Intravenous Administration Articles & Analysis
13 news found
In the study, the cell-based product was successfully delivered into the brain of mice via intranasal administration utilizing Kurve Therapeutics’ patented Controlled Particle Dispersion® technology as a novel approach to bypass the blood-brain barrier. ...
Clinical data demonstrating initial safety and efficacy from the RESKUE trial are being presented by Chief Medical Officer Maria Escolar, M.D., at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT), October 11-14, 2022 Subjects treated with FBX-101 have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter ...
“These data reaffirm our commitment to developing TSC as an adjuvant to standard of care therapy for hypoxic solid tumors, for which we are discussing a novel clinical protocol design for our planned Phase 2 Hypoxic Tumor Trial with the US Food and Drug Administration. We expect to initiate this trial in the second half of ...
ByCervoMed
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector therapy induces greater immune response than single-vector therapy in preclinical setting and translates into significant reduction of viral load HOOKIPA Pharma Inc. ...
Cerevast’s RVO Technology will combine intravenous administration of Lantheus’ microbubbles with non-invasive ultrasound delivered across the closed eyelid. ...
TG6002: Clinical proof-of-concept of the intravenous administration of an oncolytic virus presented at major congresses in 2021. ...
Both centres will image EMI-137 in real time at the cellular level using endomicroscopy with Cellvizio. Intravenous administration of EMI-137 leads to its selective accumulation in c-Met–expressing tumours, which can then be detected optically via fluorescent markers that are attached to the molecular imaging agent. c-Met is a receptor tyrosine kinase, ...
” Data to be presented at the ASGCT Annual Meeting include an oral presentation of a study looking at Sangamo’s innovative genetically engineered adeno-associated virus (AAV) capsid platform for delivery to the central nervous system (CNS) after cerebrospinal fluid administration. With protection from the blood-brain barrier, current gene delivery to the CNS ...
The special properties of ParvOryx allow for both intratumoral and intravenous administration as well as repeated application. H-1PV does not affect normal cells and is not pathogenic for humans. ...
The special properties of ParvOryx allow for both intratumoral and intravenous administration as well as repeated application. H-1PV does not affect normal cells and is not pathogenic for humans. ...
The patients received ParvOryx at three increasing dose levels, partly administered intravenously on four consecutive days, followed by an intrametastatic injection into a single liver metastasis after 6 to 13 days. ...
Cerevast’s RVO Technology will combine intravenous administration of Lantheus’ microbubbles with non-invasive ultrasound delivered across the closed eyelid. ...
Fluorescence colonoscopy in patients receiving intravenous EMI-137 enabled the visualisation of all neoplastic polyps that were visible with white light, and additionally, detected previously missed polyps that were not visible with white light alone. ...